Form 4: Twist Bioscience CEO Sells Shares for Tax Obligations

Sentiment:

Insider Transaction Report 25 August 2025 4:05 PM

Twist Bioscience CEO Emily M. Leproust sold 2,716 shares of common stock at $25.964 per share to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp, reported a transaction involving company common stock.
On August 21, 2025, 2,716 shares of common stock were disposed of at a price of $25.964 per share.
This sale was a "sell to cover" transaction, mandated by the Issuer's equity incentive plans, to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units, and was not a discretionary trade.
Following this transaction, Ms. Leproust directly beneficially owns 637,005 shares of common stock.
The filing also details various employee stock options held by Ms. Leproust with exercise prices ranging from $5.95 to $67.85, and expiration dates extending to August 31, 2030.
A performance stock option for 64,950 shares, granted on September 1, 2020, vested on December 19, 2022, after applicable performance criteria were met.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is neutral in terms of market sentiment. It does not indicate a change in the insider's view of the company's prospects.

Positives

The vesting of Restricted Stock Units and performance stock options indicates the achievement of prior performance criteria and continued service by the CEO.
The transaction is non-discretionary, meaning it does not reflect a change in the CEO's personal investment sentiment towards the company.

Negatives

A reduction of 2,716 shares in the CEO's direct beneficial ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

The sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This insider transaction report is specific to Twist Bioscience Corp and its CEO's equity compensation. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

Shareholders: Minimal impact. The sale is small relative to the company's market capitalization and the CEO's total holdings, and it's non-discretionary.
Employees: No direct impact mentioned.
Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Date	Description
09/01/2016	Vesting start date for employee stock option with $5.95 exercise price.
09/28/2017	Vesting start date for employee stock option with $8.82 exercise price.
10/31/2019	Vesting start date for employee stock option with $26.66 exercise price.
09/01/2020	Grant date for performance stock option with $67.85 exercise price.
10/24/2020	Vesting start date for employee stock option with $23.33 exercise price.
12/19/2022	Vesting date for performance stock option with $67.85 exercise price, due to performance criteria met.
08/21/2025	Date of common stock disposition to cover tax withholding obligations.
08/25/2025	Signature date of the Form 4 filing.
09/28/2025	Expiration date for employee stock option with $5.95 exercise price.
09/28/2027	Expiration date for employee stock option with $8.82 exercise price.
11/18/2028	Expiration date for employee stock option with $26.66 exercise price.
10/23/2029	Expiration date for employee stock option with $23.33 exercise price.
08/31/2030	Expiration date for performance stock option with $67.85 exercise price.

Recommendation

hold

This Form 4 filing details a routine, non-discretionary 'sell to cover' transaction by the CEO to satisfy tax obligations on vested equity. Such transactions are common and do not typically signal a change in the company's fundamentals or the insider's long-term outlook. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

Twist Bioscience, TWST, Emily M. Leproust, Insider Trading, Form 4, Stock Sale, Equity Compensation, Restricted Stock Units, Performance Options, Biotechnology, Synthetic Biology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.